- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.12.24 | Fibrosis-focused Tvardi to go public via merger with cash-strapped Cara | ||
| 18.12.24 | Roche to bring mass spec to routine labs with new cobas system's European approval | ||
| 18.12.24 | Holoclara wriggles roundworm-derived molecule into phase 1, burrowing into eosinophilic esophagitis | ||
| 18.12.24 | Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug | ||
| 18.12.24 | Novo Nordisk taps Photys for $186M cardiometabolic collab | ||
| 18.12.24 | Aurion's regenerative eye disease med improves vision in phase 1/2 trial | ||
| 18.12.24 | Novo Holdings leads SiteOne's $100M series C for non-opioid pain treatments | ||
| 18.12.24 | Cognition's phase 2 SHIMMER results finally allow dementia drug to shine | ||
| 17.12.24 | BD, Babson Diagnostics expand fingertip blood draws to urgent care clinics, doctors' offices | ||
| 17.12.24 | Dexcom taps generative AI lifestyle tips for its Stelo glucose sensor | ||
| 17.12.24 | Sanofi, Teva look to 'next frontier' in IBD treatment after TL1A antibody hits mark in midstage trial | ||
| 17.12.24 | Biomea's diabetes drug improves glucose control 3 months after FDA hold lifted | ||
| 17.12.24 | Cash-strapped Portage finds hope in sale of lead asset, subsidiary to Immunova | ||
| 17.12.24 | Fresh off $120M raise, AI-powered Terray is teaming up with Gilead in multi-pronged R&D pact | ||
| 17.12.24 | Merck drops TIGIT asset and LAG-3 program, discontinuing several phase 3 trials | ||
| 16.12.24 | American Society of Hematology member surveys identify barriers to improving diversity in clinical trials | ||
| 16.12.24 | Boston Scientific recalls pacemakers at risk of triggering permanent safety mode | ||
| 16.12.24 | UCB's orchestra hits dud note: Novartis-partnered Parkinson's asset fails phase 2 | ||
| 16.12.24 | Roche mothballs another hemophilia A gene therapy under Spark amid plans to debut new hematologic asset | ||
| 16.12.24 | Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies | ||
| 16.12.24 | BMS keeps axing deals inked under old leadership, this time culling cell therapy pacts with Century, Immatics | ||
| 16.12.24 | Fluid Biomed raises $27M for its bioabsorbable brain aneurysm stent | ||
| 16.12.24 | Reviva's antipsychotic shows promise against schizophrenia symptoms in year-long study | ||
| 16.12.24 | FDA hits pause on another of PepGen's muscular dystrophy trials | ||
| 16.12.24 | Foghorn gives up on sole wholly owned clinical asset after phase 1 leukemia failure |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
